Camurus AB (OSTO:CAMX) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CAMX Camurus AB OSTO:CAMX
86 GF Score
Price kr634.50
GF Value kr701.24
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

OSTO:CAMX
86GF Score
Camurus AB OSTO:CAMX
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (OSTO:CAMX) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of kr634.50 is trading 9.5% below its estimated GF Value™ of kr701.24. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for OSTO:CAMX:

  • Total Noninterest Expense:
  • GF Value™: kr701.24 vs. price of kr634.50 (9.5% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the OSTO:CAMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
86GF Score

Get the complete analysis for OSTO:CAMX

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr634.50
Price
kr701.24
GF Value